Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-Grade Gliomas

Neurosurgery. 2006 Jun;58(6):1099-107; discussion 1099-107. doi: 10.1227/01.NEU.0000215944.81730.18.

Abstract

Objective: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs.

Methods: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression.

Results: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 +/- 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 +/- 62 days (P < 0.005). Lesions with low baseline rCBV (< 1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (> 1.75) demonstrated progressively increasing tumor volumes over time.

Conclusion: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk-benefit equation and postsurgical adjuvant therapy for LGGs.

Publication types

  • Duplicate Publication

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Astrocytoma / diagnosis
  • Astrocytoma / pathology
  • Astrocytoma / surgery
  • Astrocytoma / therapy*
  • Blood Volume
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / pathology
  • Brain Neoplasms / surgery
  • Brain Neoplasms / therapy*
  • Cerebrovascular Circulation
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Oligodendroglioma / diagnosis
  • Oligodendroglioma / pathology
  • Oligodendroglioma / surgery
  • Oligodendroglioma / therapy*
  • Predictive Value of Tests
  • Reference Standards
  • Survival Analysis
  • Treatment Outcome